TREATMENT OF RAYNAUD SYNDROMES WITH PIRACETAM(NOOTROPIL R),NOOTROPIC AND ANIPLATELET AGENT

1987 ◽  
Author(s):  
M Moriau ◽  
E Lavenne-Pardonge ◽  
C H Col-De Beys
Keyword(s):  
Systemic Disease ◽  
The Other ◽  
Optimal Dosage ◽  
Double Blind Study ◽  
Inhibiting Activity ◽  
Synergic Effect ◽  
Double Blind ◽  
The Third ◽  
Daily Aspirin ◽  
Platelet Functions

Three prospective studies have been performed with piracetam (Nootropil ®-) in the treatment of Raynaud disease and syndromes.The first one, realized in 20 cases of Raynaud disease established that 8 g piracetam daily was the optimal dosage necessary to obtain a significant clinical, ultrasonic and biologic improvement.In the second one, 58 cases of Raynaud syndromes (47 idiopathic and 11 associated with systemic disease) were treated with 8 g daily piracetam during 6 to 12 months. A clinical and ultrasonic improvement was observed in 75 and 80 % of the cases and a normalisation of the disturbed platelet functions (36/58) in 88 %. Moreover a benefic rheologic effect was noted and related to the membrane deformability, the antiplatelet and the Von Willebranc factor synthese or release inhibiting activity of piracetamThe third one realized in cross over in 30 cases of Raynaud syndromes compare the effects of piracetam alone (dosage 8 g daily) with the combination piracetam (4 g daily) - aspirin (100 mg daily) or with other drugs like buflomedil, calcium antagonists and ketanserine.A synergic effect was obtained with the combination piracetam -aspirine and piracetam alone seems to be more efficient than the other drugs.A fourth double blind study is actually performed

A Double-Blind Comparative Study with Dolo-Neurobion® and its Separate Constituents in the Treatment of Polyneuritis

1974 ◽  
Vol 2 (1) ◽  
pp. 32-35 ◽  
Author(s):  
E Reyes-Armijo
Keyword(s):  
Comparative Study ◽  
The Other ◽  
Blind Study ◽  
Vitamin B ◽  
Double Blind Study ◽  
Double Blind

A double-blind study was carried out with Dolo-Neurobion® and matching tablets containing: the vitamin B combination, and the metamizol component of the preparation. Forty-five patients suffering from polyneuritis were each treated with eight tablets a day for fourteen days. All fifteen patients who received Dolo-Neurobion were free from pain after treatment but this result was not observed in the patients treated with the vitamin combination alone nor with the metamizol component of the preparation. Dolo-Neurobion also proved more successful after the first half of the treatment (one week), the degree of pain being reduced more significantly than with the other two forms of medication.

scholarly journals F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study

Blood ◽  
1993 ◽  
Vol 81 (1) ◽  
pp. 9-14 ◽  
Author(s):  
RL Nagel ◽  
E Vichinsky ◽  
M Shah ◽  
R Johnson ◽  
E Spadacino ◽  
...  
Keyword(s):  
Steady State ◽  
Side Effects ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Recombinant Human Erythropoietin ◽  
The Other ◽  
Double Blind Study ◽  
Double Blind ◽  
Human Erythropoietin ◽  
Iron Deficient

Abstract Studies on baboons and preliminary observations in three patients with sickle cell anemia (SS) suggested that high doses of pulse administered recombinant human erythropoietin (rHuEPO) stimulate F-reticulocyte production. We now report on the administration of rHuEPO in a double- blind format to ascertain frequency of response and potential precipitation of side effects. Ten patients were enrolled, but one was discontinued due to the indication of a blood transfusion. Of the other nine, five received rHuEPO in escalating doses (from 400 to 1,500 U per kg twice daily [BID] per week), alternating with a placebo, in blinded fashion. The second group, consisting of four patients, followed an identical protocol (except starting dose was 1,000 U/Kg, BID per week) and were iron supplemented during treatment. The criterion of response was a transient doubling (as a minimum) of the steady-state F- reticulocyte level. We found that none of the five patients in the first group responded to rHuEPO, and two of them became iron deficient, as judged by a significant decrease in ferritin. Of the second group, four patients responded with F-reticulocyte increases. In three patients, open label administration of rHuEPO confirmed the effect. We observed seven painful episodes during this study, two during the EPO administration and five during the placebo arm. Three patients were phlebotomized because the hemoglobin level increased 1.5 g/dL more than steady-state levels. Of the six patients followed-up by percent dense cell determinations, one exhibited increased levels during periods of the treatment, whereas the other five showed no change. No anti-rHuEPO antibodies were detected. We conclude that rHuEPO can stimulate F- reticulocyte response in some patients with sickle cell anemia, without apparent negative clinical side effects. The state of iron stores may be critical. Whether higher doses of rHuEPO and/or a different regimen might induce sustained F cells and fetal hemoglobin increases remains to be determined.

Danni microvascolari nell'impotenza erettile di “origine psicogena”

1997 ◽  
Vol 64 (1_suppl) ◽  
pp. 103-109
Author(s):  
F. Albergati ◽  
P. Lattarulo ◽  
S.B. Curri ◽  
H. Jallous ◽  
C. Marandola ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Contractile Activity ◽  
Double Blind Study ◽  
Double Blind ◽  
Duration Of Action ◽  
Laser Doppler Flow ◽  
Doppler Flow ◽  
The Third ◽  
Erectile Impotence ◽  
Site Of Action

Erectile impotence is one of the major reasons for uro-andrological consultation. Countless experimental and clinical data are by now available regarding the importance of the pathologies of penile microcirculation as primitive cause of erectile dysfunction with the result that microangiological evaluation in andrology is being used more and more. Up to the present, however, there has been a lack of data related to the action of penile manipulation “in itself (necessary for correct topical application of substances with microvasculokinetic action) on the contractile activity of the arterioles examined by Laser-Doppler Flow. This report gives the results of a clinical study on 400 patients with erectile dysfunction treated with topically administered microvasculokinetic therapies. All the patients underwent a complete microangiological assessment to detect the presence of microcirculatory pathologies responsible for the erectile dysfunction. In a double blind study three different substances were used topically: two proved to nave microvasculokinetic activity with a different duration of action, while the third was totally inert. The first two increased the penile arteriolar contractile capacity in all the patients, while the third had no effect, showing that manipulation “in itself has no effect which helps increase penile arteriolar sphygmic activity. Furthermore, the different duration of action between the two substances acting on the microcirculation highlights the importance of using suitably complexed molecules for crossing the cutaneous barrier and reaching the site of action in patients who respond positively to the microvasculokinesis test.

scholarly journals Treatment of common warts with the immune stimulant Propionium bacterium parvum

2012 ◽  
Vol 87 (4) ◽  
pp. 585-589 ◽  
Author(s):  
Nilton Nasser
Keyword(s):  
Immune System ◽  
Mucous Membrane ◽  
Saline Solution ◽  
Immune Status ◽  
Intradermal Injection ◽  
The Other ◽  
Double Blind Study ◽  
Double Blind ◽  
Immune Modulator ◽  
Common Warts

BACKGROUND: Warts are epithelial proliferations in the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in size and number according to the patient's immune status. The Propionium bacterium parvum is a strong immune stimulant and immune modulator and has important effects in the immune system and it is able to produce antibodies in the skin. OBJECTIVE: To show the efficacy of the Propionium bacterium parvum in saline solution in the treatment of skin warts. METHODS: A randomized double-blind study. Twenty patients with multiple warts were divided into two groups: one received 0,1ml intradermal injection of placebo solution in just one of the warts and the other received 0,1 ml of saline solution of Propionium bacterium parvum, one dose a month, for 3 to 5 months. RESULTS: Among the 20 patients who participated in the study, ten received the placebo and ten received the saline solution with Propionium bacterium parvum. In 9 patients treated with the Propionium bacterium parvum solution the warts disappeared without scars and in 1 patient it decreased in size. In 9 patients who received the placebo no change to the warts was observed and in 1 it decreased in size. CONCLUSIONS: The immune modulator and immune stimulant Propionium bacterium parvum produced antibodies in the skin which destroyed the warts without scars, with statistically significant results (P<0,001), and cured 90 % of the patients. We suggest the use of the immune stimulant in the treatment of warts.

scholarly journals A Comparative Study on the Effects of Ketofol, Dexmedetomidine, and Isofol in Anesthesia of Candidates for Dilatation and Curettage

2022 ◽  
Vol 11 (6) ◽  
Author(s):  
Mahzad Yousefian ◽  
Ali Mohammadian Erdi ◽  
Negin Haghshenas
Keyword(s):  
The Other ◽  
Blood Oxygen ◽  
Hemodynamic Changes ◽  
Blood Oxygen Saturation ◽  
Double Blind ◽  
The Third ◽  
Dilatation And Curettage ◽  
Double Blind Clinical Trial ◽  
Class 1 ◽  
Control Pain

Background: Dilatation and curettage (D & C) is one of the relatively common surgeries among women. Familiarity with the analgesics, along with their different uses and specific characteristics, can help to determine the best and most appropriate drug to control pain in the patients. Objectives: This study aimed to compare the effects of ketofol, dexmedetomidine, and isofol in anesthesia of candidates for D & C. Methods: In this double-blind clinical trial, 150 candidates for D & C surgeries with ASA class 1 and 2 were included. Patients were randomly divided into three groups. The first group received ketamine + propofol, the second group received dexmedetomidine, and the third group received isofol (isoflurane + propofol). Any hemodynamic changes or respiratory disorders, including apnea or hypoventilation, drop in the level of blood oxygen saturation, and the need for respiratory support, were recorded and compared. Results: Hypoventilation was observed in 47 patients in isofol group, 18 in the dexmedetomidine group, and 42 in ketofol group. Also, 48 patients in the isofol group, eight in the dexmedetomidine group, and 33 in the ketofol group experienced apnea. Moreover, 17 patients in the dexmedetomidine group, 35 in the ketofol group, and eight in the isofol group experienced bradycardia. The rate of bradycardia was significantly higher in the dexmedetomidine group (70%) compared to the other two groups, and the rate of hypotension was significantly higher in the isofol group (P = 0.001). Conclusions: According to the results, dexmedetomidine was associated with fewer complications during general anesthesia in D & C surgery.

scholarly journals F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study

Blood ◽  
1993 ◽  
Vol 81 (1) ◽  
pp. 9-14 ◽  
Author(s):  
RL Nagel ◽  
E Vichinsky ◽  
M Shah ◽  
R Johnson ◽  
E Spadacino ◽  
...  
Keyword(s):  
Steady State ◽  
Side Effects ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Recombinant Human Erythropoietin ◽  
The Other ◽  
Double Blind Study ◽  
Double Blind ◽  
Human Erythropoietin ◽  
Iron Deficient

Studies on baboons and preliminary observations in three patients with sickle cell anemia (SS) suggested that high doses of pulse administered recombinant human erythropoietin (rHuEPO) stimulate F-reticulocyte production. We now report on the administration of rHuEPO in a double- blind format to ascertain frequency of response and potential precipitation of side effects. Ten patients were enrolled, but one was discontinued due to the indication of a blood transfusion. Of the other nine, five received rHuEPO in escalating doses (from 400 to 1,500 U per kg twice daily [BID] per week), alternating with a placebo, in blinded fashion. The second group, consisting of four patients, followed an identical protocol (except starting dose was 1,000 U/Kg, BID per week) and were iron supplemented during treatment. The criterion of response was a transient doubling (as a minimum) of the steady-state F- reticulocyte level. We found that none of the five patients in the first group responded to rHuEPO, and two of them became iron deficient, as judged by a significant decrease in ferritin. Of the second group, four patients responded with F-reticulocyte increases. In three patients, open label administration of rHuEPO confirmed the effect. We observed seven painful episodes during this study, two during the EPO administration and five during the placebo arm. Three patients were phlebotomized because the hemoglobin level increased 1.5 g/dL more than steady-state levels. Of the six patients followed-up by percent dense cell determinations, one exhibited increased levels during periods of the treatment, whereas the other five showed no change. No anti-rHuEPO antibodies were detected. We conclude that rHuEPO can stimulate F- reticulocyte response in some patients with sickle cell anemia, without apparent negative clinical side effects. The state of iron stores may be critical. Whether higher doses of rHuEPO and/or a different regimen might induce sustained F cells and fetal hemoglobin increases remains to be determined.

The Effects of Carbon Monoxide on Dual-Task Performance

1979 ◽  
Vol 21 (1) ◽  
pp. 13-24 ◽  
Author(s):  
Vernon R. Putz
Keyword(s):  
Carbon Monoxide ◽  
Human Performance ◽  
Response Times ◽  
Blood Levels ◽  
Double Blind Study ◽  
Double Blind ◽  
Monitoring Task ◽  
The Third ◽  
Tracking Condition ◽  
Intensity Changes

Thirty adult, nonsmokers were exposed for four hours to one of three concentrations of carbon monoxide (CO) 5 ppm, 35 ppm, and 70 ppm to produce blood levels of either 1%, 3%, or 5% carboxyhemoglobin (COHb) after the third hour of exposure. Performance in the double blind study was assessed by a tracking task paired with a peripheral monitoring task, each possessing two levels of difficulty. The results indicated that visual-manual tracking was significantly impaired by about 30%, during the fourth hour of exposure to 70 ppm of CO, when 5% COHb was reached, as compared to performance at 5 ppm and 35 ppm. The impairment occurred only during the high frequency tracking condition. Response times of subjects to the peripheral light-intensity-changes also increased during the third and fourth hours. The findings suggested that an assessment of the effects of low-level CO on human performance should include an analysis of the demand characteristics of the tasks as well as data on concentration and exposure duration.

The Effect of Ticlopidine on Platelet Functions in Acute Myocardial Infarction

1985 ◽  
Vol 53 (03) ◽  
pp. 332-336 ◽  
Author(s):  
J Bjerre Knudsen ◽  
E Kjøller ◽  
K Skagen ◽  
J Gormsen
Keyword(s):  
Acute Phase ◽  
Coagulation Factors ◽  
Inhibitory Effect ◽  
Double Blind Study ◽  
Double Blind ◽  
Infarction Size ◽  
Increased Risk ◽  
Group A ◽  
Pain Patients ◽  
Platelet Functions

SummaryA group of 43 consecutive patients with AMI were randomized to treatment with a novel platelet inhibitor, ticlopidine, or placebo in a double blind study. Treatment was started within 12 hr after onset of precordial pain. Patients who had taken drugs with known platelet inhibitory effect prior to the onset of therapy were excluded.Platelet survival time (PS) was measured 24–36 hr after onset of precordial pain and after 3 months of treatment in both groups. In the early phase of AMI CK-MB and ASAT were taken twice daily for estimation of infarction size. Platelet function, coagulation factors and fibrinolysis parameters were followed sequentially for 21 days and repeated after 3 months.In the placebo group a significant reduction in PS (5.62 ± 1.63 S. D. days) was measured in the acute phase of AMI compared to PS 3 months after infarction (8.03 ± 1.20 S.D. days). In the ticlopidine group PS was normal during the acute phase (8.35 ± 1.82 S.D. days). After 3 months of treatment PS was normal in both groups. During the first two weeks after AMI significant changes in coagulation parameters and fibrinolysis indicated an increased risk of thrombosis in both groups. These parameters were unaffected by the platelet inhibitory therapy. Estimated by peak CK-MB and ASAT, infarction size was significantly reduced in the ticlopidine group.

A comparative study between lithium and extended-release carbamazepine in acute mania: a double-blind clinical trial

2020 ◽  
Vol 09 ◽  
Author(s):  
Saeed Shoja Shafti ◽  
Hamid Kaviani
Keyword(s):  
Extended Release ◽  
Rating Scale ◽  
Lithium Carbonate ◽  
Acute Mania ◽  
Prolonged Release ◽  
Double Blind Study ◽  
Double Blind ◽  
Global Improvement ◽  
The Third ◽  
The Mean

Background: Recently, numerous large clinical trials have been performed to evaluate the effectiveness and tolerability of extended-release formulations of carbamazepine in bipolar disorder. Objective: In the current study we compared lithium with a prolonged-release form of carbamazepine (Tegretol CR), to evaluate its efficiency and safety in a group of patients with diagnosis of acute mania. Method: Fifty patients with diagnosis of acute mania, entered into a three-week, double-blind study, for random assignment to lithium carbonate or tegretol CR. The main outcome measure in the present evaluation was the Manic State Rating Scale (MSRS), which was scored at baseline and weekly intervals up to the third week. Moreover, insight and overall illness severity and improvement were assessed using the Schedule for Assessment of Insight (SAI), the Clinical Global Impressions-Global Improvement scale (CGI-I), and the Clinical Global Impressions Severity Scale (CGI-S), respectively. While statistical significance had been defined as p value ≤0.05, treatment efficacy had been analyzed by independent samples t-test and repeated measures analysis of variance (ANOVA). Results: Despite the fact that the mean total score of MSRS improved significantly by both lithium carbonate and tegretol CR at the end of the third week, between-group analysis showed significant advantage of lithium, regarding both frequency and intensity of symptoms, at the end of study. The mean total score of SAI, as well, showed significant improvement by both of them. Nevertheless, while the CGI-I demonstrated significant improvement by participants taking lithium and tegretol CR, the CGI-S showed significant progress only by lithium. Besides, the Cohen’s effect size analysis showed large improvement of MSRS by lithium and medium improvement by tegretol CR. Post-hoc power analysis showed an intermediate power of 0.42 on behalf of the current evaluation. Conclusion: While both lithium carbonate and tegretol CR were valuable for improvement of manic symptoms, management with lithium appears to be more helpful.

Sign in / Sign up

Export Citation Format

Share Document